J Lung Cancer.  2006 Dec;5(2):92-95. 10.6058/jlc.2006.5.2.92.

Mutational Analysis of PUMA Gene in Non-small Cell Lung Cancers

• Yoo NJ
• Lee JW
• Lee SH
• Lee SH

• KMID: 2200168
• DOI: http://doi.org/10.6058/jlc.2006.5.2.92

Abstract

PURPOSE: It has become clear that, together with proliferation, deregulation of apoptosis plays a pivotal role in tumorigenesis, and the somatic mutations of apoptosis-related genes have been reported in human cancers. PUMA, a pro- apoptotic member of Bcl-2 family, mediates p53-deependent and -independent apoptosis. The aim of this study was to explore whether alteration of PUMA protein expression is a characteristic of human lung cancers.
MATERIALS AND METHODS
To explore the possibility that the genetic alterations of PUMA might be involved in the development of human cancers, we analyzed the entire coding region and all splice sites of human PUMA gene in 100 human non-small cell lung cancers (NSCLCs) by polymerase chain reaction (PCR)-based single-strand conformation polymorphism (SSCP).
RESULTS
The PCR-SSCP analysis detected no mutation in the entire coding regions and all splice sites of human PUMA gene in the 100 NSCLCs.
CONCLUSION
The data presented here suggested that PUMA gene mutation may not contribute to the pathogenesis of human NSCLCs.

Keyword

Non-small cell lung cancer; PUMA; Apoptosis; Mutation

MeSH Terms

Apoptosis
Carcinogenesis
Carcinoma, Non-Small-Cell Lung
Clinical Coding
Humans
Lung Neoplasms*
Lung*
Polymerase Chain Reaction
Puma*

Figure

• 

  Fig. 1 Representative SSCP of PUMA gene in the non-small cell lung cancers. The exon 2 of the PUMA oene were amplified by PCR using a specific primer set. The PCR products from the representative cases of non-small cell lung cancers were visualized on SSCP. SSCP of DNA from the non-small cell lung cancers (T) shows no aberrant bands as compared to SSCPs from the normal tissues (N),

Reference

1.Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000. 39:1415–1430.

2.Nagata S. Apoptosis by death factor. Cell. 1997. 88:355–365.

3.Hanahan D., Weinberg RA. The hallmarks of cancer. Cell. 2000. 100:57–70.

4.Datta SR., Katsov A., Hu L, et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell. 2000. 6:41–51.

5.O'Connor L., Strasser A., O'Reilly LA, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 1998. 17:384–395.

6.Inohara N., Ding L., Chen S., Nunez G. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X (L). EMBO J. 1997. 16:1686–1694.

7.Guo B., Godzik A., Reed JC. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem. 2001. 276:2780–2785.

8.Oda E., Ohki R., Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000. 288:1053–1058.

9.Nakano K., Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001. 7:683–694.

10.Chang J., Clark GM., Allred DC., Mohsin S., Chamness G., El ledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003. 97:545–553.

11.Krajewska M., Zapata JM., Meinhold-Heerlein I, et al. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia. 2002. 4:129–140.

12.McDonnell TJ., Deane N., Platt FM, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989. 57:79–88.

13.Lee JH., Soung YH., Lee JW, et al. Inactivating mutation of the pro-apoptotic gene BID in gastric cancer. J Pathol. 2004. 202:439–445.

14.Kondo S., Shinomura Y., Miyazaki Y, et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res. 2000. 60:4328–4330.

15.Rampino N., Yamamoto H., Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997. 275:967–969.

16.Lee JW., Soung YH., Kim SY, et al. Inactivating mutations of proapoptotic Bad gene in human colon cancers. Carcinogenesis. 2004. 25:1371–1376.

17.Lee SH., Shin MS., Park WS, et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 1999. 18:3754–3760.

18.Lee SH., Shin MS., Kim HS, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 1999. 59:5683–5686.

19.Soung YH: Lee JW: Kim SY, et al. Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene. 2005. 24:141–147.

20.Kim HS., Lee JW., Soung YH, et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology. 2003. 125:708–715.

21.Soung YH., Lee JW., Kim SY, et al. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res. 2005. 65:815–821.

22.Soung YH., Lee JW., Kim HS, et al. Inactivating mutations of CASPASE-7 gene in human cancers. Oncogene. 2003. 22:8048–8052.

23.Soung YH., Lee JW., Kim HS, et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet. 2004. 115:112–115.